While you slept, our AI read every SEC Form 4 filed overnight and ranked the insider trades that matter — open-market buys and sells, cluster activity, executive conviction, and stakes that are large relative to the company.
▲ Insider Buys
▼ Insider Sells
#
Ticker
Company
Insiders
Total
% of Mcap
Score
AI Commentary
Insider Trading Scan
While you slept, our AI read every SEC Form 4 filed overnight and ranked the insider trades that matter — open-market buys and sells, cluster activity, executive conviction, and stakes that are large relative to the company.
720 Form 4 filings scanned26 tickers with open-market buys$22.77M total insider buying
OVERNIGHT SCAN — AI BRIEFING · INSIDER BUYING
Tonight's open-market P purchases span technology, healthcare, industrials and energy, with coordinated insider clusters in Netskope, Energizer Holdings, and Artiva Biotherapeutics highlighted alongside large single-name bets. The largest trades come from Netskope and Energizer, reflecting multi-insider clusters totaling roughly 0.141% and 0.171% of market cap, respectively, while Artiva shows a RA Capital-led cluster. Across all reported names, total purchases amount to about $22.64 million, signaling notable insider conviction across multiple sectors.
William J.G. Griffith (Director) bought 306,399 shares (~$3.77M). The same number of shares was purchased by ICONIQ Strategic Partners VIII entities and Makan Divesh (all 10% Owners), forming a 5-insider cluster totaling about 0.141% of Netskope's market cap; a coordinated signal from both insiders and major owners.
RA Capital Management and affiliates (RA Capital Healthcare Fund LP; RA Capital Nexus Fund; RA Capital Nexus Fund III, L.P.) plus Kolchinsky Peter (Director) each purchased 21,654 shares (~$194,040). This 6-insider cluster totals about $1.16M, signaling coordinated healthcare-focused insider interest in Artiva Biotherapeutics (mcap ~$118M; ~0.165% of mcap).
Kevin Tang (10% Owner) and Tang Capital Management LLC (10% Owner) each bought 249,946 shares (~$891,067), forming a 2-insider cluster representing about 0.198% of Fulcrum Therapeutics' market cap.